The financing round was led by Talis Capital with participation from multiple angels and existing backers.
"We are delighted to have received such credible investor support to continue on our mission to empower and support those with cancer. It’s imperative that we start understanding how therapies are affecting patients: for pharmaceutical companies, our technology enables deeper patient understanding which leads to better drugs, greater differentiation and faster licensing, as well as the ability to provide personalised scalable support to patients. For patients, this means better care and improved outcomes from cancer. We’re now looking forward to applying our rich data and machine learning capabilities to novel predictive analytics to generate even richer insights for our life science partners."
Morningside led the Series B financing to support regulatory approvals and market entry for clinical software treatments.
"At ieso, we’re looking to transform global mental health by unlocking the power of clinical data to develop AI-enabled digital therapeutics. Our experience delivering outstanding mental health care within the NHS ideally places us for starting to tackle this challenge. A new generation of clinically-validated digital mental health care products could ultimately improve millions of lives. But we cannot do this alone, and look forward to working with our patients, clinicians, investors, as well as existing and future partners, to better serve those who require mental health support."
The funding round includes backing from strategic and regional investors to support the rollout of Female Hormone Mapping.
"Today, more and more people are realising that understanding and measuring your body’s biochemistry is key for a long and healthy life. For women in particular, gaining unique insight into how their hormone levels fluctuate throughout their unique cycle can give women the support they have been lacking and help to close the gender health gap"
The financing round was led by First Capital Ventures with participation from existing investors.
"We are delighted to welcome First Capital Ventures as our latest and first U.S. investor alongside the continued commitment from our existing investor base."
